July 10, 2008 - Shanghai, China - WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Dr. Debra Yu as the Vice President of Strategy.
Prior to joining WuXi PharmaTech, Dr. Yu worked at Pfizer Inc., where she co-led Pfizer's venture capital group and was instrumental in working in diverse areas such as diagnostics, asset monetization and creative finance structures and Pfizer's innovation agenda.
Earlier she was a General Partner at Delphi Ventures and a Managing Director at Bay City Capital, two leading Bay area venture firms focused on the life sciences.
In addition, Dr. Yu
has held senior positions at many leading companies and organizations like McKinsey & Co., the U.S. Food and Drug Administration
(FDA), the Wilkerson Group, Morgan Stanley & Co., Genentech Inc. and the Permanente Company
She has stewarded more than 25 companies through venture capital, and sat on the board of eight and stepped in as Chief Executive Officer of one.
responsibilities in her
new role include bringing constructive leadership and stewardship to the company's strategic planning and initiatives.
Dr. Yu will report directly to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
"I am very pleased to welcome Debra on board to further increase the depth of our senior management," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
"With 19 years of experiences in venture capital and life sciences, Debra
will provide strategic guidance as we continue building a global drug and medical device R&D service platform through organic growth, partnership and M&A."
Dr. Yu received her BA in Molecular Biology from Princeton University, New Jersey in 1986 and her MD from Harvard Medical School, Massachusetts in 1992.